ChyloCure is a biotechnology and healthcare startup founded in 2020. The company's flagship product, Chylobinoid, is a premium offering comprising 70% CBDa, about 5% CBD, 5% other cannabinoids, 4% magnesium, and naturally occurring plant lipids. This distinctive formula provides a convenient and consistent method for safe dosing, offering significant health benefits over traditional medicinal cannabinoids. The company recently secured a $150.00K debt financing investment on 25 January 2021, indicating investor interest in its innovative products and potential for growth. This investment would likely support the company's research and development efforts, as well as its market expansion plans. With a focus on biotechnology and healthcare, ChyloCure has the potential to make an impact in the rapidly evolving cannabinoid-based products market.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Debt Financing | $150.00K | - | 25 Jan 2021 |
No recent news or press coverage available for ChyloCure.
We care about your data, and we'd love to use cookies make your experience better.
